Abrégé

A method of separation of sperm cells with undamaged intact heads from sperm cells with damaged heads and/or somatic cells and/or cell debris in a sperm sample obtained from a human, comprising the steps of: providing an anti-CD46 antibody or CD46-binding ligand bound to a carrier and/or to a tag; contacting the sperm sample with the anti-CD46 antibody or CD46 -binding ligand bound to the carrier and/or to the tag in order to bind CD46 presenting cells and/or cell debris from the sperm sample to the anti-CD46 antibody or CD46-binding ligand; removing the CD46 presenting cells bound via the anti-CD46 antibody or CD46 -binding ligand to the carrier and/or to the tag to obtain a sperm sample free of CD46 presenting cells, wherein CD46 presenting cells include sperm cells with damaged heads, somatic cells and cell debris, is disclosed.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to a novel antibody binding to the RBD of the Spike protein of the SARS-CoV-2. The antibody recognizes a conservative conformational epitope of the Spike RBD protein, inhibits Spike RBD – ACE2 binding, and inhibits viral infection in Virus Neutralization Test (VNT). The inhibition of the viral infection was observed for the wild-type SARS-CoV-2 (variant B.1.) as well as for the variants of concern alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and omicron (B.1.1.529) of the SARS-CoV-2. The invention further provides the method for detecting and quantifying protective antibodies recognizing the SARS-CoV-2 Spike protein using the novel antibody.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

The present invention provides a method of separation of sperm cells with undamaged intact heads from sperm cells with damaged heads and/or somatic cells and/or cell debris in a sperm sample obtained from an animal, comprising the steps of: - providing an anti-CD46 antibody or CD46-binding ligand bound to a carrier and/or to a tag; - contacting the sperm sample with the anti-CD46 antibody or CD46-binding ligand bound to the carrier and/or to the tag in order to bind CD46 presenting cells and/or cell debris from the sperm sample to the anti-CD46 antibody or CD46-binding ligand; - removing the CD46 presenting cells bound via the anti-CD46 antibody or CD46-binding ligand to the carrier and/or to the tag to obtain a sperm sample free of CD46 presenting cells, wherein CD46 presenting cells include sperm cells with damaged heads, somatic cells and cell debris. This technology is designed to separate sperm with undamaged intact heads to be further used in assisted reproduction, medicine (in particular breeding programs and veterinary medicine), storage purpose, and/or research.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides a method of separation of sperm cells with undamaged intact heads from sperm cells with damaged heads and/or somatic cells and/or cell debris in a sperm sample obtained from a human, comprising the steps of: - providing an anti-CD46 antibody or CD46-binding ligand bound to a carrier and/or to a tag; - contacting the sperm sample with the anti-CD46 antibody or CD46-binding ligand bound to the carrier and/or to the tag in order to bind CD46 presenting cells and/or cell debris from the sperm sample to the anti-CD46 antibody or CD46-binding ligand; - removing the CD46 presenting cells bound via the anti-CD46 antibody or CD46-binding ligand to the carrier and/or to the tag to obtain a sperm sample free of CD46 presenting cells, wherein CD46 presenting cells include sperm cells with damaged heads, somatic cells and cell debris. The technology of the invention is in particular designed to separate sperm with undamaged intact heads to be further used in assisted reproduction, human medicine and/or research.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The present invention provides a polypeptide mimicking epitope of glycoprotein gp120 of HIV-1 virus, which is recognized by a paratope of broadly neutralizing antibody VRC01, has the length up to 100 amino acid residues and contains an amino acid sequence: X1YKNX2INX3AX4X5VX6X7VKRX8IDX9ILAX10LP (SEQ ID NO. 1),, in which: X1is selected from amino acids A, N, R; X2is selected from amino acids A, R, D; X3is selected from amino acids R, V, P; X4is selected from amino acids V, L, S; X5is selected from amino acids T, G, R; X6is selected from amino acids G, T; X7is selected from amino acids L, A; X8is selected from amino acids V, I; X9is selected from amino acids G, A, R; X10 is selected from amino acids R, A, G; with a directly attached alpha-helical structure at the N-terminus or C-terminus.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/12 - Antigènes viraux

Abrégé

D of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 49/00 - Préparations pour examen in vivo
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention provides deferoxamine derivatives of general formula I and pharmaceutically acceptable salts thereof, (I) wherein at least one of R1 and R2 is a substituent of formula II. The novel derivatives are particularly suitable as medicaments, preferably for the treatment of cancer. Pharmaceutical preparations of compounds of formula I and a metal, preferably gallium, are also provided, resulting in even more active medicaments or contrast agents. Combinations with other agents, resulting in synergistic effects, are provided.

Classes IPC  ?

• C07F 9/54 - Composés de phosphonium quaternaire
• A61K 31/66 - Composés du phosphore
• A61P 35/00 - Agents anticancéreux

Abrégé

D of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 49/00 - Préparations pour examen in vivo
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammations, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia.

Classes IPC  ?

• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
• C07F 9/54 - Composés de phosphonium quaternaire

Abrégé

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammations, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia.

Classes IPC  ?

• C07F 9/54 - Composés de phosphonium quaternaire
• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon

Abrégé

The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA- specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention provides triphenylphosphonium biguanide analogs of general formula (I), whereas the general formula (I) includes resonance structures and pharmaceutically acceptable salts, protonated form as well as free base, (Formula (I)) where each one of R1, R2, R3, R4, R5, R6, R7 is independently selected from the group comprising H; C1-C6 alkyl; C6-C10 aryl; (C1-C6)alkyl(C6-C10)aryl; -C(=O)-R'; -C(=O)OR'; -C(=O)NR'R"; -C(=S)R'; -C(=S)NR'R''; wherein R' and R" are independently selected from the group comprising H, C1-C6 alkoxy, C1-C6 alkyl, C6-C10aryl, (Cl-C6)alkyl(C6-C10)aryl; whereas C1-C6 alkoxy, C1-C6 alkyl, C6-C10 aryl, (C1-C6)alkyl(C6-C10)aryl can be unsubstituted or substituted by one or more substituents selected independently from the group comprising C1-C4 alkyl, N(H or C1-C4 alkyl)2, wherein alkyls are the same or different, phenyl, benzyl, OH, SH, F, CI, Br, I, C1-C4alkoxy, C1-C4 acyloxy, C1-C4 mercapto; and substituent of general formula (II) (Formula (I)) wherein Z is as defined in the claims, whereas at least one of R1, R2, R3, R4, R5, R6, R7 is the substituent of general formula (II), X- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid, Y- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid. The invention further provides a method of preparation of these derivatives. These new compounds are suitable in particular for the treatment of diabetes mellitus type 2 and/or pancreatic carcinoma.

Classes IPC  ?

• C07F 9/54 - Composés de phosphonium quaternaire
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61P 35/00 - Agents anticancéreux
• A61K 31/66 - Composés du phosphore

Abrégé

The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n = 6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.

Classes IPC  ?

• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C07F 9/54 - Composés de phosphonium quaternaire

Abrégé

The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n = 6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.

Classes IPC  ?

• C07F 9/54 - Composés de phosphonium quaternaire
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon

Abrégé

The present invention provides a novel class of polypeptides (REX binders), derived from an albumin-binding domain of the streptococcal protein G that inhibit binding of human IL-23 cytokine to its cognate IL-23 receptor. Blocking of interaction between p19/IL-23 subunit with the receptor leads to the suppresion of IL-23-dependent pro-inflammatory signaling pathway, resulting in an inhibitory effect on IL-23-stimulated Th-17 cell expansion. The invention further provides a DNA sequence encoding for such polypeptides and host cells containing such sequence. The polypeptides of the invention are useful as therapeutics and diagnostics.˙

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques